Univariate Analysis for OS and PFS
| OS | PFS | ||||
| Variable | n | HR and 95% CI | P | HR and 95% CI | P |
| Positive resection margin | 0.587 | 0.351 | |||
| No | 38 | 1 | 1 | ||
| Yes | 44 | 1.2 (0.6–2.3) | 1.3 (0.7–2.5) | ||
| Size of primary | 0.030 | 0.009 | |||
| <2 cm | 61 | 1 | 1 | ||
| 2–5 cm | 20 | 2.6 (1.2–5.3) | 2.7 (1.4–5.2) | ||
| >5 cm | 4 | 1.7 (0.4–7.2) | 1.7 (0.4–7.1) | ||
| Conventional stage | 0.002 | <0.001 | |||
| Stage I/II | 63 | 1 | 1 | ||
| Stage III | 34 | 2.6 (1.4–5.0) | 3.2 (1.8–5.7) | ||
| PET stage | <0.001 | <0.001 | |||
| Stage I/II | 53 | 1 | 1 | ||
| Stage III | 44 | 3.7 (1.9–7.2) | 3.1 (1.7–5.6) | ||
| Presence of nodal disease on PET | <0.001 | <0.001 | |||
| No | 57 | 1 | 1 | ||
| Yes | 40 | 5.5 (2.8–10.8) | 4.9 (2.7–9.0) | ||
| Primary treatment modality | 0.013 | 0.028 | |||
| Surgery | 26 | 1 | 1 | ||
| Surgery and RT or chemoradiation therapy | 45 | 0.4 (0.2–0.9) | 0.5 (0.3–1.1) | ||
| RT or chemoradiation alone | 26 | 1.3 (0.6–2.8) | 1.3 (0.7–2.6) | ||
| Presence of active metabolic disease | <0.001 | <0.001 | |||
| No | 48 | 1 | 1 | ||
| Yes | 31 | 4.5 (2.2–9.4) | 3.3 (1.7–6.4) | ||
| Lymphovascular invasion | 0.015 | 0.079 | |||
| No | 65 | 1 | 1 | ||
| Yes | 19 | 2.3 (1.2–4.7) | 1.8 (0.9–3.6) | ||
| Primary site | 0.512 | 0.400 | |||
| Head and neck | 43 | 1 | 1 | ||
| Lower limb | 28 | 0.6 (0.3–1.4) | 0.6 (0.3–1.3) | ||
| Upper limb or trunk | 26 | 0.9 (0.4–1.9) | 0.8 (0.4–1.5) | ||